The company officially inaugurated a new 45,000-square-foot manufacturing facility at the Longbridge Business Park in the West Midlands
Waters Corporation has experienced a transformative year in 2024, characterised by the opening of a cutting-edge facility, numerous product innovations, and significant leadership appointments.
The company officially inaugurated a new 45,000-square-foot manufacturing facility at the Longbridge Business Park in the West Midlands. This state-of-the-art facility more than triples Waters Corporation’s existing operations, enhancing its machining capacity for producing vital components for products developed at its Mass Spectrometry Centers of Excellence in Wilmslow, UK, and Wexford, Ireland.
In November, Waters Corporation launched the waters_connect Data Intelligence software, a cloud-based application designed for regulated industries. This innovative software integrates with the Waters Empower Chromatography Data System (CDS) to streamline laboratory information management, improve audit readiness, and facilitate faster decision-making.
In October, the company introduced a comprehensive suite of enzymes, reagents, and waters_connect software designed specifically for large-molecule RNA therapeutics. This workflow simplifies sequence and modification confirmation using LC-MS analysis, thus accelerating the development of RNA-based pharmaceuticals, including CRISPR sgRNA and mRNA therapeutics.
Additionally, in October, Waters unveiled the TA Instruments Discovery Core Rheometer, which is intended for quality control across various industries. It features an intuitive touchscreen interface and supports materials such as battery slurries, printing inks, food, and personal care products.
In August, Waters Corporation appointed Heather Knight to its Board of Directors. Knight is currently the Executive Vice President and Group President of Medical Products and Therapies at Baxter International, bringing extensive experience to her new role.
In July, Waters launched the global release of the TA Instruments Rapid Screening-Differential Scanning Calorimeter (RS-DSC), which provides high-throughput thermal stability testing capabilities for biopharmaceutical developers focused on antibody drugs and engineered proteins.
In June, the Xevo MRT, the highest-performing benchtop mass spectrometer, was introduced. This innovation combines MRT and hybrid QTof technologies to deliver exceptional resolution and speed for epidemiological studies.
Over 40 products in Waters’ liquid chromatography (LC) portfolio received ACT Ecolabels, highlighting the company’s commitment to sustainability in the scientific community.
In May, the next-generation ACQUITY QDa II Mass Detector was launched, offering a compact, cost-effective solution for mass spectral data analysis across various industries, thereby enhancing the ACQUITY Premier Liquid Chromatography portfolio.
In April, Waters launched the GTxResolve Premier SEC 1000Å 3-micron Columns, utilising advanced materials to enhance the development of gene-based therapeutics.
The new Alliance iS Bio HPLC System introduced advanced bio-separation technology and intelligent features that streamline quality control in biopharma.
In March, Waters unveiled new Oasis WAX/GCB and GCB/WAX Cartridges, which simplify PFAS analysis while ensuring QC-tested accuracy for regulated laboratories. An accessory for the TA Instruments Discovery Hybrid Rheometers now allows simultaneous electrical impedance and rheological measurements, which is beneficial for battery research.
In February, Waters Corporation launched HPLC CONNECT software, which enables seamless synchronization between Waters HPLC/UPLC systems and Wyatt Technology’s MALS instruments, thus boosting efficiency in biopharmaceutical research.
With these advancements and strategic initiatives, Waters Corporation continues to drive innovation and excellence in analytical instrumentation and laboratory solutions.
